Prolotherapy Injection: Difference between revisions

From WikiMSK

mNo edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{stub}}
{{stub}}
{{nonmainstream}}
{{Controversial}}
See Hauser et al for a free open access systematic review from 2016. <ref>{{#pmid:27429562}}</ref>
See Hauser et al for a free open access systematic review from 2016.<ref>{{#pmid:27429562}}</ref>The most commonly use agent is dextrose usually in concentrations between 5-20%. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.
The most commonly use agent is dextrose. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.
 
== Articles ==
{{PDF|Fullerton2018.pdf|Prolotherapy for the thoracolumbar fascia - Fullerton 2018}}


==References==
==References==

Latest revision as of 16:10, 26 March 2022

This article is a stub.
This page or section deals with a controversial topic.
Please use your clinical judgement.

See Hauser et al for a free open access systematic review from 2016.[1]The most commonly use agent is dextrose usually in concentrations between 5-20%. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.

Articles

References

  1. Hauser et al.. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clinical medicine insights. Arthritis and musculoskeletal disorders 2016. 9:139-59. PMID: 27429562. DOI. Full Text.

Literature Review